Zevra Therapeutics, Inc. (ZVRA)
12.30
+0.24
(+1.95%)
USD |
NASDAQ |
Sep 02, 16:00
12.30
0.00 (0.00%)
After-Hours: 19:41
Zevra Therapeutics Research and Development Expense (TTM) : 14.83M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 14.83M |
| March 31, 2026 | 13.78M |
| December 31, 2025 | 12.70M |
| September 30, 2025 | 16.83M |
| June 30, 2025 | 22.72M |
| March 31, 2025 | 28.25M |
| December 31, 2024 | 35.71M |
| September 30, 2024 | 39.45M |
| June 30, 2024 | 42.35M |
| March 31, 2024 | 40.75M |
| December 31, 2023 | 38.61M |
| September 30, 2023 | 34.41M |
| June 30, 2023 | 27.16M |
| March 31, 2023 | 24.42M |
| December 31, 2022 | 18.86M |
| September 30, 2022 | 15.36M |
| June 30, 2022 | 12.55M |
| March 31, 2022 | 10.72M |
| December 31, 2021 | 9.904M |
| September 30, 2021 | 10.15M |
| June 30, 2021 | 9.682M |
| March 31, 2021 | 8.852M |
| Date | Value |
|---|---|
| December 31, 2020 | 8.777M |
| September 30, 2020 | 8.179M |
| June 30, 2020 | 10.01M |
| March 31, 2020 | 12.86M |
| December 31, 2019 | 19.26M |
| September 30, 2019 | 23.18M |
| June 30, 2019 | 32.97M |
| March 31, 2019 | 38.65M |
| December 31, 2018 | 41.76M |
| September 30, 2018 | 40.99M |
| June 30, 2018 | 33.95M |
| March 31, 2018 | 28.12M |
| December 31, 2017 | 20.59M |
| September 30, 2017 | 23.03M |
| June 30, 2017 | 21.02M |
| March 31, 2017 | 21.36M |
| December 31, 2016 | 20.48M |
| September 30, 2016 | 17.22M |
| June 30, 2016 | 17.27M |
| March 31, 2016 | 15.05M |
| December 31, 2015 | 13.93M |
| September 30, 2015 | 15.13M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Innoviva, Inc. | 28.66M |
| Collegium Pharmaceutical, Inc. | -- |
| Johnson & Johnson | 15.06B |
| Ligand Pharmaceuticals, Inc. | 41.35M |
| Harrow, Inc. | 20.56M |